26 Ott Impact of bone marrow fibrosis and early response on outcome after azacitidine therapy in 94 patients with myelodisplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia Posted at 13:23h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Bruno Fattizzo Read More
26 Ott NGS-target capture for ALL Posted at 13:20h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Grazia Fazio Read More
26 Ott Prognostic impact of additional molecular lesions in Ph+ acute lymphoblastic leukemia (ALL) Posted at 13:18h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Anna Lucia Fedullo Read More
26 Ott Chromothripsis in acute myeloid leukemia Posted at 13:17h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Maria Chiara Fontana Read More
26 Ott Evaluation of minimal residual disease by ASO-RQ-PCR in multiple myeloma: results from 2 phase III studies in patients treated with lenalidomide after front-line therapy Posted at 13:15h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Manuela Gambella Read More
26 Ott Negative pre transplant minimal residual disease, assessed by flow cytometry Posted at 13:14h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Massimiliano Gambella Read More
26 Ott Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia Posted at 13:09h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Andrea Ghelli Luserna di Rorà Read More
26 Ott RNA seq in refractory/relapsed T-ALL Posted at 13:08h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Valentina Gianfelici Read More
26 Ott Integrated molecular and clinical profiling to optimize outcome prediction in splenic marginal zone lymphoma Posted at 13:06h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Manuel Gotti Read More
26 Ott High feasibility and efficacy of minimal residual disease directed therapy in patients affected by AML with mutated NPM1 Posted at 13:05h in Comunicazioni orali 2016 by Anna Scotti (staff) 0 Comments 0 Likes Fabio Guolo Read More
